55435-71-7

Basic information

• Product Name: 4-(2-CHLORO-4-NITRO-PHENYL)-MORPHOLINE
• Synonyms: BUTTPARK 45\09-18;4-(2-CHLORO-4-NITRO-PHENYL)-MORPHOLINE;AKOS B035658;N-(2-CHLORO-4-NITROPHENYL)MORPHOLINE;TIMTEC-BB SBB006363;3-chloro-4-morpholino-1-nitrobenzene;Einecs 259-638-5;Morpholine, 4-(2-chloro-4-nitrophenyl)-
• CAS NO: 55435-71-7
• Molecular Formula: C₁₀H₁₁ClN₂O₃
• Molecular Weight: 242.66
• EINECS: 259-638-5
• Mol File: 55435-71-7.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 399.6°C at 760 mmHg
• Flash Point: 195.5°C
• Appearance: /Solid
• Density: 1.374g/cm³
• Vapor Pressure: 1.36E-06mmHg at 25°C
• Refractive Index: 1.589
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(2-CHLORO-4-NITRO-PHENYL)-MORPHOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-CHLORO-4-NITRO-PHENYL)-MORPHOLINE(55435-71-7)
• EPA Substance Registry System: 4-(2-CHLORO-4-NITRO-PHENYL)-MORPHOLINE(55435-71-7)

Safety Data

• TSCA: Yes
• Hazardous Substances Data: 55435-71-7(Hazardous Substances Data)

Usage

Uses

4-(2-Chloro-4-nitrophenyl)morpholine

InChI:InChI=1/C10H11ClN2O3/c11-9-7-8(13(14)15)1-2-10(9)12-3-5-16-6-4-12/h1-2,7H,3-6H2

Upstream product

• 110-91-8 morpholine 
• 99-54-7 3,4-dichloronitrobenzene 
• 10389-51-2 1-morpholino-4-nitrobenzene 
• 100-00-5 4-chlorobenzonitrile 
• 41252-96-4 3-chloro-4-iodonitrobenzene 
• 350-30-1 3-chloro-4-fluoronitrobenzene 
• 3209-22-1 1,2-Dichloro-3-nitrobenzene 

Downstream Products

• 1542258-49-0 3-(3-chloro-4-morpholinophenyl)-2,6-dimethylpyrimidin-4(3H)-one 
• 1542259-45-9 (2Z)-3-amino-N-(3-chloro-4-morpholinophenyl)but-2-enamide 
• 1542259-44-8 N-(3-chloro-4-morpholinophenyl)-3-oxobutanamide 
• 869785-51-3 4-(2-chloro-4-nitrophenyl)morpholin-3-one 
• 104686-94-4 (3-chloro-4-morpholin-4-yl-phenyl)-(7-methyl-1⁽³⁾H-imidazo[4,5-f]quinolin-9-yl)-amine 
• 55048-24-3 3-chloro-4-morpholinoaniline 

Relevant articles and documents

Facile preparation of 4-(4-nitrophenyl)morpholin-3-one via the acid-catalyzed selective oxidation of 4-(4-nitrophenyl)morpholine by sodium chlorite as the sole oxidant

4-(4-Nitrophenyl)morpholin-3-one and 4-(4-aminophenyl) morpholin-3-one are the key intermediates for rivaroxaban synthesis. A facile and economically efficient process has been developed for the preparation of these intermediates. Excellent yield of 4-(4-nitrophenyl)morpholine is obtained by condensing 4-chloro nitrobenzene and morpholine, and 4-(4- nitrophenyl)morpholine is oxidized using inexpensive sodium chlorite to achieve a good yield of the corresponding 4-(4- nitrophenyl)morpholin-3-one. Finally, the key intermediate of rivaroxaban, 4-(4-aminophenyl) morpholin-3-one, is achieved by the iron(III)-catalyzed reduction of the nitro group with aqueous hydrazine. No high-cost materials were used, and the process did not require column purification.

AMINOAMIDE COMPOUNDS

Compounds with amino amide linkers and pharmaceutical compositions and medicaments comprising such compounds are disclosed. The compounds modulate protein function of 1L-1β, IL-2, IL-6, TNF-α, CK1α, GSPT1, aiolos, ikaros or helios, or combinations thereof. In addition, methods of making such compounds and their uses for treating or ameliorating diseases, disorders, or conditions associated with protein malfunction, such as cancer, are provided.

NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS

The invention relates to the field of medicine, discloses new nitrogen heterocyclic derivatives, preparation method thereof and as medicament in particular as the treatment and prevention of treating tissue fibrosis of the medicament. The invention also discloses a pharmaceutically acceptable compound of the present invention comprise a pharmaceutical composition and methods for using the composition for the treatment of the human or animal tissue fibrosis of diseases, in particular for treating the human or animal renal interstitial fibrosis, glomerular sclerosis, hepatic fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, skin fibrosis, after the operation of adhering, benign prostate hypertrophy, bone-myocardial, scleroderma, multiple sclerosis, pancreas fibrosis, liver cirrhosis, myosarcoma, neurofibromatosis, interstitial pulmonary fibrosis, diabetic nephropathy, Alzheimer's disease or vascular fibrosis disease in use. (by machine translation)